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Background: Plasmodium vivax is the predominant species of human malaria parasites present in China. Although
sulphadoxine-pyrimethamine (SP) and chloroquine (CQ) have been widely used for malaria treatment in China, the
resistance profiles of these drugs are not available. Analysis of dihydrofolate reductase (dhfr), dihydropteroate
synthase (dhps), and multidrug resistance (mdr-1) gene mutations in P. vivax isolates is a valuable molecular
approach for mapping resistance to SP and CQ. This study investigates the prevalence of pvdhfr, pvdhps, and
pvmdr-1 of P. vivax clinical isolates from China and provides baseline molecular epidemiologic data on SP- and
CQ-associated resistance in P. vivax.
Methods: Plasmodium vivax clinical isolates were collected from two malaria-endemic regions of China, subtropical
(Xishuangbanna, Yunnan province) and temperate (Bozhou, Anhui province), from 2009 to 2012. All isolates were
analysed for single nucleotide polymorphism haplotypes in pvdhfr, pvdhps, and pvmdr-1 using direct DNA sequencing.
Results: In pvdhfr, 15% of Xishuangbanna isolates carried wild-type (WT) allele, whereas the majority of isolates
carried mutant genes with substitutions at five codons. Eight mutant haplotypes of pvdhfr were detected, while
limited polymorphism of pvdhfr was found in Bozhou isolates. A size polymorphism was present in pvdhfr, with
the three-repeat type being the most predominate in both Xishuangbanna (79%) and Bozhou (97%) isolates. In
pvdhps, mutations at four codons were detected in Xishuangbanna isolates leading to six haplotypes, including
WT allele, single-mutation, double-mutation, and triple-mutation alleles. All Bozhou isolates carried WT pvhdps. In
pvmdr-1, isolates from Xishuangbanna carried mutations at codons Y976F and F1076L, whereas all isolates from
Bozhou had only a single mutation at codon F1076L.
Conclusions: Plasmodium vivax isolates from subtropical and temperate zones of China are shown to have
dramatically different frequencies and patterns of mutations in pvdhfr, pvdhps, and pvmdr-1. Whereas P. vivax
populations in subtropical China are highly resistant to SP and CQ, those in the temperate zone may still be
susceptible to SP and CQ. This information is useful for establishing treatment policy and provides a baseline for
molecular surveillance of drug-resistant P. vivax in these areas.
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Plasmodium vivax infects approximately 100 million people
annually and endangers 40% of the world’s population [1].
Malaria has been a significant public health problem in
China until recently, predominantly in two areas of China:
subtropical zone (Yunnan and Hainan provinces) and
temperate zone (such as Anhui, Henan, Hunan, Hubei,
and Jiangsu provinces). Due to China’s national malaria
control programme launched in 1978, the intensity and
scale of vivax malaria outbreaks have decreased dramatic-
ally through vector control and drug treatment of febrile
individuals [2]; however, malaria incidence rose steadily
between 2000 and 2006 [3]. In subtropical China, Yunnan
is one of the two provinces with year-round local trans-
mission of P. vivax and Plasmodium falciparum and has
suffered one of the highest malaria morbidity and mortal-
ity rates in China. In temperate zone of Central China,
outbreaks of malaria have been reported in Anhui and
Henan provinces. In 2006, malaria prevalence increased
considerably, with the highest numbers of malaria cases
reported in Anhui province [4]. Although malaria inci-
dence is low in China, the areas and populations at risk
are large. P. vivax malaria accounted for > 95% of all mal-
aria cases reported in China in 2007 [5], having become
the sole parasite species and responsible for more than
90% of re-emerged malaria cases reported in temperate
zone of China in 2009 [6]. In 2010, a countrywide malaria
elimination policy was launched by the Ministry of Health
of P. R. China with the goal of eliminating malaria by 2015
in China—with the exception of the border region in Yun-
nan province, and to completely eliminate malaria from
China by 2020. Therefore, there is an urgent need to
monitor vivax malaria transmission and drug resistance in
subtropical and temperate zones of China.
Resistance to common anti-malarial drugs, such as
chloroquine (CQ), has been reported for P. vivax around
the world, including Indonesia [7], Myanmar [8], India [9],
Vietnam [10], Turkey [11], and Ethiopia [12]. CQ and
primaquine have been used as first-line therapies for rad-
ical cure of vivax malaria in China for the past 60 years,
and clinical failures or reduced efficacy of CQ-primaquine
drug combinations for treating vivax malaria had been re-
ported at the Yunnan-Myanmar border [13], in Yunnan
[14] and Anhui [15] provinces. Although sulphadoxine-
pyrimethamine (SP) is rarely used to treat patients with
P. vivax malaria, pyrimethamine, a component of the two
combination regimens [Maloprim® (plus dapsone) and
Fansidar® (plus sulphadoxine)], has been widely used for
malaria prophylaxis in China between the mid-1960s and
early 1990s [16]. This may place P. vivax under the selec-
tion of SP drug stress in China, especially in the subtrop-
ical zone where P. vivax and P. falciparum mixed-species
infections were common. P. vivax malaria re-emerged in
many counties of China in recent years, possibly causedby social and environmental changes and intrinsic differ-
ences in parasites with long or short relapse patterns
[17-20]. Even changes in mosquito strains or species could
favour a subpopulation of vivax parasites and lead to
changes in the parasite population structure [21], and the
emergence and spread of drug-resistant malaria should, of
course, be held accountable. Studies in other P. vivax-
endemic regions such as Vietnam highlight the geographic
heterogeneity and temporal dynamics of drug resistance in
P. vivax [10], raising further concerns about the presence
of clinical resistance to SP and CQ in these areas of China
and highlighting the importance of continued surveillance
of CQ drug efficacy.
Molecular genetic markers of resistance are useful for
monitoring the emergence and spread of anti-malarial
drug resistance; a better understanding of the mecha-
nisms of drug action and resistance are essential for ful-
filling the promise of eradicating malaria [22]. Currently,
several genetic markers, including dihydrofolate reduc-
tase (dhfr), dihydropteroate synthase (dhps), and multi-
drug resistance (mdr-1), have been used to study the
prevalence and spread of SP- and CQ-resistant P. vivax
[23-26]; however, molecular epidemiologic information
on P. vivax parasite resistance to CQ and primaquine in
China is limited. This study investigated the frequencies
and patterns of mutations in pvdhfr, pvdhps, and pvmdr-1
linked to SP and CQ resistance in P. vivax isolates from
Yunnan and Anhui provinces of China, and the results
provide important information for molecular surveillance
of drug-resistant P. vivax in these areas.
Methods
Study areas
The study was conducted in areas in subtropical (Xishuang-
banna prefecture, Yunnan province) and temperate
(Bozhou city, Anhui province) zones of China (Figure 1).
Xishuangbanna prefecture had a population of around
113,000 in 2010. It is located in southern Yunnan (the
south-west area of China), bordering Myanmar in the
west and Laos and Vietnam in the south, in an area be-
tween 21°08’ and 22°36’ latitude and 99°56’ and 101°50’
longitude. Its climate is characterized by a cool, dry
winter, and a warm, wet summer. It has a distinct sea-
sonal climate characterized by rainy season from May
to October and dry season from November to May, an
average temperature of 18–22°C and average rainfall of
1100–2400 mm per year.
Xishuangbanna was a highly endemic area for both P.
falciparum and P. vivax malaria. Five confirmed Anopheles
species are widely distributed throughout Yunnan province,
with the predominant malaria vectors being Anopheles
minimus and Anopheles dirus [27]. Transmission in the
study area is seasonal, and malaria incidence characterized
by peaks of infection occurring from June to July and again
Figure 1 Map of Yunnan in subtropical zone and Anhui province in temperate zone of China. Shown are the locations of Xishuangbanna
prefecture and Bozhou city where P. vivax isolates were collected. Scale bar = 400 kilometers.
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around 485,000 in 2010. It is located in the north-west of
Anhui (temperate zone of China) bordering six provinces:
Jiangsu in the south-east, Shandong in the north, Hubei in
the west, Henan in north-west, Jiangxi in the south, and
Zhejiang in the north-east, located in an area between 32°
51’ and 35°05’ latitude and 115°53’ and 116°49’ longitude.
The area has a distinct seasonal climate characterized by
humid summer from June to September and dry winter
from October to December, with an average temperature
of 14–17°C and average rainfall of 500–750 mm per year
[16]. Bozhou city was an endemic area for P. vivax malaria,
and the main malaria vector was Anopheles sinensis and
the secondary vector Anopheles anthropophagus.
Blood sample collection
Blood samples were collected from patients with symp-
tomatic P. vivax malaria admitted to local hospitals for
anti-malarial drug treatment. Inclusion criterion was pa-
tients infected with P. vivax but no other human malaria
species as confirmed by peripheral smear examination.
Preparation and staining of blood slides were done fol-
lowing the World Health Organization procedures for
basic malaria microscopy. Thick and thin blood smears
were checked after staining with Giemsa. A total of 114
P. vivax clinical isolates (blood samples) were collected
from patients with symptomatic P. vivax malaria ad-
mitted to local hospitals for anti-malarial drug treatment
(n = 53) in Xishuangbanna, Yunnan province, from June
2011 to October 2012 and (n = 61) in Bozhou city,
Anhui province, from June 2009 to October 2010 (col-
lected earlier than those of Xishuangbanna samples).Two patients from Bozhou city had a travel history outside
of Anhui; all others had no history of travel to neighbour-
ing provinces or countries. All the Xishuangbanna isolates
were collected from the border of Myanmar. After in-
formed consent from all adults or legal guardians of chil-
dren, a 1.0 mL sample of whole blood was collected from
vivax malaria patients in EDTA tubes and stored at −20°C
until DNA extraction. This study was reviewed and ap-
proved by the Ethics Committee of Sun Yat-sen University,
China (IRB 2009A0101).
DNA extraction for pvdhfr, pvdhps, and pvmdr-1
Plasmodium vivax genomic DNA was extracted from
200 μL of each blood sample using a DNA blood kit fol-
lowing the manufacturer’s instructions (Takara Bio Inc.,
Shiga, Japan) with minor modifications. The DNA was
dissolved in TE buffer (10 mM Tris–HCl, 0.1 M EDTA,
pH 8.0) and stored at −20°C until use. The quality of
total DNA was analysed by running 5 μL of each DNA
sample on a 1.0% agarose gel stained with ethidium
bromide and visualized under ultraviolet illumination.
Polymerase chain reaction (PCR) amplification for pvdhfr,
pvdhps, and pvmdr-1
To amplify pvdhfr, pvdhps, and pvmdr-1, a nested PCR
amplification method was used following previously re-
ported protocols with some minor modifications [15,16,28].
Oligonucleotide primers and cycling conditions are listed
in Table 1. All amplification reactions were carried out in a
total volume of 25 μL containing 17.0 μL of dH2O, 1.0 μL
of each primer (10 pM), 1.5 μL of MgCl2 (25 mM), 0.5 μL
of Taq polymerase (5 U/μL), 0.5 μL of dNTP mixture
Table 1 Sequences of primers and cycling conditions used to amplify pvdhfr, pvdhps, and pvmdr-1 of Plasmodium vivax
isolatesa,b
Genesc Primersd PCR cycling conditionse Product size (bp) Reference




pvdhfr (S) F: 5’- CCCCACCAC ATA ACG AAG-3’ 95°C 5 min/[95°C 30 s, 58°C 30 s, 68°C 45 s] × 30 cycles,
68°C 7 min
755 [16]
R: 5’- CCC CACCTT GCTGTA AACC-3’
















aP. vivax isolates from Yunnan and Anhui provinces.
bThe data provided oligonucleotide primers and cycling conditions of pvdhfr, pvdhps, and pvmdr-1 genes.
cP, Primary PCR reaction; S, Secondary PCR reaction.
dF, Forward primer; R, Reverse primer.
eCycling conditions were modified in the present study.
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manufacturer’s instructions (BioBasic Inc., Markham, ON,
Canada). Primary amplification reactions were initiated with
1.0 μL of template genomic DNA prepared from the blood
samples, and 1.0 μL of primary reaction amplification was
used in secondary amplification reactions. The amplified
nested PCR products were resolved on 1.0% agarose gel,
and the sizes of the PCR products were determined using
a 100-bp DNA ladder (NewProbe, Beijing, China). The
nested PCR products were stored at −20°C until analysis.
Sequence analysis of pvdhfr, pvdhps, and pvmdr-1
The nested PCR products of pvdhfr, pvdhps, and pvmdr-1
from the above samples were directly sequenced in both di-
rections, using an ABI PRISM3730 DNA sequencer from
Sangon Biotech (Shanghai, China). Nucleotide and amino
acid sequences of pvdhfr, pvdhps, and pvmdr-1 were aligned
and compared with the following published sequences
of pvdhfr (accession no. X98123), pvdhps (accession no.
AY186730), and pvmdr-1 (accession no. AY618622) using
Clustal W of the BioEdit 7.0 program.
Statistical analysis
Statistical significance was determined with SPSS soft-
ware (version 13.0). U test was used to compare the
prevalence of infection between collection sites. P < 0.05
was considered statistically significant.
Results
Prevalence and patterns of mutant pvdhfr in P. vivax isolates
All blood samples (n = 114) were shown to be infected
with P. vivax only by microscopy. The pvdhfr gene wassuccessfully amplified from all 114 P. vivax isolates.
Mutations at codons F57I/L, S58R, T61M, H99R/S, and
S117N/T were detected in the 53 Xishuangbanna iso-
lates, accounting for 60%, 62%, 62%, 19%, and 74% of
the isolates examined, respectively (Table 2); no muta-
tions at pvdhfr positions I13 or I173 were found in the
Xishuangbanna isolates. Only H99S and S117N were de-
tected in the 61 Bozhou isolates, with frequencies of
40% and 57% isolates, respectively. Mutant codon S117N
was the most prevalent in both Xishuangbanna and
Bozhou areas, accounting for 74% and 57% of isolates
examined, respectively. Haplotype analysis of pvdhfr for
all Xishuangbanna isolates revealed eight distinct allelic
forms (Table 3), including the wild-type (WT) allele
(I13/F57/S58/T61/H99/S117/I173), two single-mutant
alleles (99S and 117N), three double-mutant alleles
(99S/117N, 99R/117N, and 58R/99N), and two quadru-
ple mutant alleles (57I/58R/61M/117T and 57L/58R/
61M/117T). Of the eight allelic variants, the most preva-
lent allelic variants were quadruple-mutant alleles (57L/
58R/61M/117T) (53%, 28/53) among Xishuangbanna
isolates, followed by WT allele (15%, 8/53) and a single-
mutant allele H99S (11%, 6/53). The remaining five
allelic variants were only detected in 21% (11/53) of
P. vivax isolates examined from Xishuangbanna. Four al-
lelic variants [WT allele, single-mutant alleles (99S and
117N), and a double-mutant allele (99S/117N)] were de-
tected in 61 isolates from Bozhou, with a single-mutant
allele (117N) being predominant (42%, 26/61) (Table 3).
In addition to the above point mutations, variations at
the central tandem repeat region between amino acid po-
sitions 88 and 105 of pvdhfr were also detected. Analysis
Table 2 Prevalence of mutations conferring resistance to chloroquine and sulfadoxine-pyrimethemine in Plasmodium
vivax isolatesa
Gene locus Number of isolates (%b)
Subtropical zone, Temperate zone, Total,
n = 53 n = 61 n = 114
dhfr Mutation at codon 13 0 (0) 0 (0) 0 (0)
Mutation at codon 57 32 (60**) 0 (0) 32 (28)
Mutation at codon 58 33 (62**) 0 (0) 33 (29)
Mutation at codon 61 33 (62**) 0 (0) 33 (29)
Mutation at codon 99 10 (19**) 24 (40) 34 (30)
Mutation at codon 117 39 (74) 35 (57) 74 (65)
Mutation at codon 173 0 (0) 0 (0) 0 (0)
dhps Mutation at codon 382 17 (32**) 0 (0) 17 (15)
Mutation at codon 383 42 (79**) 0 (0) 42 (37)
Mutation at codon 512 1 (2) 0 (0) 1 (1)
Mutation at codon 553 15 (28**) 0 (0) 15 (13)
Mutation at codon 585 0 (0) 0 (0) 0 (0)
mdr-1 Mutation at codon 976 5 (9**) 0 (0) 5 (4)
Mutation at codon 1076 19 (36**) 61 (100) 80 (70)
aIsolates from subtropical (Yunnan province) and temperate (Anhui province) zones of China.
bStatistically significant differences for comparison with isolates from temperate zone (Anhui province) of China (**P < 0.01) using u-test.
Table 3 Prevalence of single nucleotide polymorphisms and multi-mutated haplotypes in Plasmodium vivax dhfr, dhps,
and mdr-1a
Number of isolates (%b)
Genotype Subtropical zone, Temperate zone, Total,
n = 53 n = 61 n = 114
dhfr Wild-type haplotype I13F57S58T61H99S117I173 8 (15) 11 (18) 19 (17)
Single-mutant haplotype I13F57S58T61S99S117I173 6 (11) 15 (24) 21 (18)
Single-mutant haplotype I13F57S58T61H99N117I173 2 (4**) 26 (42) 28 (25)
Double-mutant haplotype I13F57S58T61S99N117I173 1 (2**) 9 (15) 10 (9)
Double-mutant haplotype I13F57S58T61R99N117I173 3 (6*) 0 (0) 3 (3)
Double-mutant haplotype I13F57R58T61H99N117I173 1 (2) 0 (0) 1 (1)
Quadruple-mutant haplotype I13L57R58M61H99T117I173 28 (53**) 0 (0) 28 (25)
Quadruple-mutant haplotype I13I57R58M61H99T117I173 4 (8*) 0 (0) 4 (4)
dhps Wild-type haplotype S382A383K512A553V585 11 (21**) 61 (100) 72 (64)
Single-mutant haplotype S382G383K512A553V585 13 (25**) 0 (0) 13 (11)
Double-mutant haplotype A382G383K512A553V585 14 (26**) 0 (0) 14 (12)
Double-mutant haplotype S382G383K512G553V585 11 (21**) 0 (0) 11 (10)
Triple-mutant haplotype A 382G383K512G553V585 3 (6*) 0 (0) 3 (3)
Triple-mutant haplotype S382G383E512G553V585 1 (2) 0 (0) 1 (1)
mdr-1 Wild-type haplotype Y976F1076 34 (65**) 0 (0) 34 (30)
Single-mutant haplotype Y976L1076 14 (26**) 61 (100) 75 (66)
Double-mutant haplotype F976L1076 5 (10**) 0 (0) 5 (4)
aIn isolates from subtropical (Yunnan province) and temperate (Anhui province) zones of China. The mutated amino acids are indicated by bold type.
bStatistically significant differences for comparison with isolates from temperate zone (Anhui province) of China (*, P < 0.05; **, P < 0.01) using u-test.
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most (89%, 101/114) of the isolates from both areas con-
tained three copies of the GGDNXX repeat that could be
divided into type A, B, and C based on substitutions in the
middle repeat (Figure 2A). The rest of the isolates (11%,
13/114) had two repeats (type D). The majority of para-
sites from both Xishuangbanna and Bozhou isolates (79%
and 97%, respectively) had the three-copy repeat type.
However, the distribution and frequency of tandem re-
peats in pvdhfr in Xishuangbanna isolates were different
from those of Bozhou isolates (Figure 2B). Type A (60%)
was the dominant allele in Xishuangbanna, whereas type
C (56%) was the most common allele among the Bozhou
isolates.
Prevalence and patterns of mutant pvdhps in P. vivax
isolates
All 114 isolates from Xishuangbanna and Bozhou were
successfully amplified for pvdhps. Sequence analysis re-
vealed that point mutations were detected at codons
S382A, A383G, K512E, and A553G, but not at V585 in
pvdhps in Xishuangbanna isolates (Table 2). Among the
above four mutants, codon S382A was the most preva-
lent, accounting for 79%, followed by codons S382A and
A553G with frequency of 32% and 28% in all Xishuang-
banna isolates, respectively; the rest of the mutant codonFigure 2 Alignment of central tandem repeat region between
amino acid positions 88 and 105 in the pvdhfr gene and
frequencies of central tandem repeat types circulating from
Xishuangbanna and Bozhou. A) Sequences were constructed to
the published amino acid sequences (accession no. X98123).
Dots (. . . .) and dashes (—) represent identical residues and
deletions, respectively. Amino acid changes resulting from
nucleotide substitutions are shown in bold. B) Frequencies of four
central tandem repeat types obtained from 53 P. vivax
Xishuangbanna isolates (black) and 61 Bozhou isolates (grey).K512E accounted for only 2% of the Xishuangbanna iso-
lates. Haplotype analysis of pvdhps in Xishuangbanna
isolates showed six distinct allelic forms, including WT
allele (S382/A383/K512/A553/V585), one single-mutant
allele (383G), two double-mutant alleles (S382A/A383G
and 383G/553G), and two triple-mutant alleles (S382A/
A383G/A553G and 383G/512E/585G) (Table 3). The
most common pvdhps alleles in Xishuangbanna isolates
were the double-mutant allele 382A/383G, followed by
single-mutant allele 383G, double-mutant allele 383G/
553G, and WT mutant, accounting for 26%, 25%, 21%,
and 21%, respectively. However, no mutation was de-
tected in any of the Bozhou P. vivax isolates (Tables 2
and 3).
Prevalence and patterns of mutant pvmdr-1 in P. vivax
isolates
All 114 samples were successfully amplified for pvmdr-1,
and mutations at codons Y976F and F1076L with the
frequencies of 4% and 70%, respectively, were detected
(Table 2); however, different mutant alleles were found
in the parasite populations from Xishuangbanna and
Bozhou. Mutant codon F1076L was detected from the
isolates of both Xishuangbanna and Bozhou (36% and
100%, respectively); whereas mutant codon Y976F was
found only in Xishuangbanna isolates (9%). Three haplo-
types existed among the parasites: WT (Y976/ F1076),
single-mutant allele (1076L), and double-mutant allele
(976F/1076L), with WT being the predominant type
(65%, 34/53) in Xishuangbanna isolates (Table 3) and the
single-mutant allele (1076L) being the only genotype
(100%, 61/61) in the Bozhou isolates (Table 3).
Haplotypes of combined pvdhfr, pvdhps, and pvmdr-1
allelic variants
Analysing variants of the three anti-malarial drug genetic
markers (pvdhfr, pvdhps, and pvmdr-1) in combination
identified a total of 28 distinct haplotypes in the 114 iso-
lates (24.5%) from both Xishuangbanna and Bozhou.
Among the haplotypes, 26 were found in Xishuangbanna
isolates (22.8%), four were found in Bozhou isolates
(3.5%), and two (Types 2 and 10) were found in both re-
gions (Additional file 1). The two most prevalent haplo-
types were Types 21 and 22, accounting for 11.3% and
13.2% of Xishuangbanna isolates, respectively; the re-
mainder haplotypes were distributed at low frequency
(1.9% to 7.5%), although the predominant haplotype in
Bozhou isolates was Type 7 (42.6%, 26/61), followed by
Types 10, 2, and 13. Disregarding the mutations at
codon 99 in pvdhfr and at codon 1076 in pvmdr-1,
which were considered to be not related with the anti-
malarial drugs, 4.4% of the 114 isolates (including Types
16, 19, and 26) had mutations in all the three genes,
pvdhfr, pvdhps, and pvmdr-1, simultaneously, whereas
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21–28) had mutations in the SP drug-related genes (dhfr
and dhps) which were found in Xishuangbanna but not
Bozhou isolates.
Discussion
Emergence and spread of CQ- or SP-resistant P. vivax
strains has been reported in many malarial regions around
the world, especially in Southeast Asia, which is responsible
for the increasing morbidity and mortality of P. vivax [29].
The use of anti-malarial drugs exhibits enormous geo-
graphic heterogeneity in subtropical and temperate zones
of China. With increasing movement of human popula-
tions, drug-resistant P. vivax populations and the parasite
transmission pattern in the regions are also changing con-
stantly. The emergence and spread of drug-resistant strains
of human Plasmodium species may be partly responsible
for re-emergence of malaria in China. SP was widely used
for malaria prophylaxis between the mid-1960s and early
1990s, and CQ-primaquine is still the first-line anti-
malarial drug for treating P. vivax malaria in China [16].
Molecular markers have been validated as tools for sur-
veillance of resistance. Analysis of point mutations in these
marker genes thus serves as a valuable molecular ap-
proach for mapping drug resistance and monitoring
malaria-control measures [30]. In this study, the profile of
mutations in marker genes associated with CQ and anti-
folate drug resistance among the P. vivax parasites ob-
tained from patients of the subtropical (Xishuangbanna in
Yunnan) and temperate (Bozhou in Anhui) zones of China
were determined to better understand the current and
changing patterns of CQ- and SP-resistant P. vivax in dif-
ferent malaria-endemic areas. The P. vivax parasite popu-
lations in subtropical and temperate zones were shown to
differ dramatically in pvdhfr, pvdhps, and pvmdr-1 allele
frequencies, i.e., P. vivax populations in subtropical zone
are mostly resistant to SP and are likely more tolerant
to CQ, whereas the majority of P. vivax populations in
the temperate zone are still effectively susceptible to SP
and CQ.
The long history of CQ use has exposed P. vivax to this
drug pressure continually in China. Clinical failures after
standard CQ treatment were reported in four cases of
P. vivax malaria in Yunnan province in 1996 [14]. A trend
of gradual decline of in vitro sensitivity to CQ had also been
documented between 2005 and 2008 in some areas of
China, especially at the Yunnan-Myanmar border and in
central China [31], and reduced efficacy of CQ combina-
tions for treating vivax malaria patients from 2007 to 2008
was reported at the Yunnan-Myanmar border [13]. The
relatively high frequency (9%) of pvmdr-1 Y976F mutation
among the Xishuangbanna isolates is consistent with the
previous reports of declining sensitivity to CQ. The Y976F
mutation had been reported in P. vivax isolates frommany malaria-endemic regions around the world, includ-
ing Indonesia [26], Thailand [32], Myanmar [32], and
Mauritania [33, and is associated with an increase in CQ
IC50 values in vitro [15]. Cases of CQ-resistant P. vivax
malaria have been reported in the areas of Yunnan border-
ing Myanmar, Laos, and Vietnam [8,10]. The long history
of CQ use, as well as frequent population movement
across the borders, may contribute to the CQ-resistant
P. vivax detected in Xishuangbanna. However, the Y976F
mutation was not detected in any Bozhou isolates, which
is consistent with the results showing that CQ is still ef-
fective in killing P. vivax parasites from the temperate
zone in an in vitro schizont maturation inhibition assay
[15]. The presence of Y976F in pvmdr-1 in Xishuangbanna
isolates suggests a trend toward decreased CQ sensitivity.
This study detected the F1076L mutation in pvmdr-1 in
100% of Bozhou isolates, which is consistent with previous
reports from Central China (100%) [26], the Republic of
Korea (100%) [26], Mauritania (100%) [26], and Madagascar
(100%) [34]; however, only 36% of Xishuangbanna isolates
had the F1076L mutation. It has been reported that the
F1076L substitution may not be linked to drug resistance
but may rather be a geographic variant [34].
SP inhibits the activities of dhps and dhfr in the folate
biosynthesis pathway of both P. falciparum and P. vivax
parasites, resulting in a synergistic anti-malarial effect
[35]. Resistance to antifolate drugs in both parasite spe-
cies is found to be involved with point mutations in dhps
and dhfr [23]. Although P. vivax infections are not gen-
erally treated with SP, the parasite is often exposed to
the drug due to mixed infections and misdiagnosis [36].
In this study, five mutations at amino acid positions 57,
58, 61, 99, and 117 and seven mutated alleles in pvdhfr
were detected in Xishuangbanna isolates, while only muta-
tions at positions 99 and 117 of pvdhfr and three mutated
alleles in pvdhfr were found in Bozhou isolates. It has been
reported that double mutation S58R and S117N in pvdhfr
may first arise under drug pressure and move toward de-
velopment of resistance to SP [23]. Interestingly, approxi-
mately 62% of Xishuangbanna isolates was found to have
double mutations at S58R/S117N, whereas no Bozhou iso-
lates were detected with these mutations. Instead, 39% of
Bozhou isolates had a single S117N mutation, indicating
that the P. vivax isolate circulating in Xishuangbanna may
be under stronger drug pressure than those in Bozhou.
The most prevalent double mutations of S58R/S117N in
Xishuangbanna isolates were similar to those in previ-
ous reports from East Timor [37], the Philippines [37],
Vietnam [37], and Pakistan [38]. Clinical studies have
shown that patients carrying triple and quadruple
pvdhfr mutant vivax parasites were more likely associ-
ated with SP treatment failure than those with WT par-
asites [39,40]. The triple and quadruple mutations in
pvdhfr have been detected in Yunnan [16], Hainan [16],
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and in some other countries including Indonesia [40],
Papua New Guinea [40] and India [42]. Similarly, 61% of
Xishuangbanna isolates had quadruple mutant alleles
(57L/58R/61M/117T and 57I/58R/61M/117T), strongly
suggesting that many Xishuangbanna P. vivax isolates are
resistant to sulphadoxine drugs. The triple and quadruple
mutations were not detected in isolates in Bozhou as
well as in other temperate areas of China (such as Wuhe
county in Anhui province) [41], Thailand [43], Vietnam
[43], Korea [43], Afghanistan [44], Pakistan [45], and
Iran [46], indicating that Bozhou P. vivax isolates may
still be sensitive to antifolate drugs.
Among mutated codons in pvdhfr, the T61M mutation
was mostly linked to the S117T mutation [23]. In the
present study, two mutations at T61M/S117T with quad-
ruple mutated alleles (57L/58R/61M/117T and 57I/58R/
61M/117T) were detected in Xishuangbanna isolates. The
observation is consistent with the early reports from
Thailand [47], but is in contrast to other reports from the
temperate zone of China (Wuhe county in Anhui province)
that most T61M mutations were found as single mutations
and arose independently [41]. In the current study, the
three-copy repeat type was the predominate type in both
Xishuangbanna (79%) and Bozhou (97%) isolates, which
was similar to the findings from India [42], Afghanistan
[44], Iran [46], and Wuhe county in Anhui province and
Luodian county in Guizhou province of China [41]. The as-
sociation between pvdhfr mutations and tandem repeat
polymorphisms has been extensively investigated and used
to predict the prevalence of drug-resistant malaria around
the world [43]. Therefore, the observations from this study
suggest increasing prevalence of antifolate-resistant para-
sites in the Xishuangbanna region. Additionally, no isolates
were detected with the four-copy repeat type from either
Xishuangbanna or Bozhou, in contrast to other reports
showing that quadruple-mutant dhfr alleles were exclu-
sively associated with the four-copy repeat type in Thailand
[23], India [42], and Myanmar [48]. Whether the four-copy
repeat type contributes to drug resistance requires further
investigation.
It has been suggested that mutations at codons 382, 383,
512, 553, and 585 in pvdhps gene are related to reduced
sensitivity to sulfadoxine [46,49]. In the present study, four
pvdhps mutations at codons S382A (32%), A383G (79%),
K512E (2%), and A553G (28%) and five mutant-allelic
types were detected in Xishuangbanna isolates, including
25% single-mutant allele (A383G), 47% double-mutant al-
lele (S382A/A383G and A383G/A553G), and 8% triple-
mutant allele (S382A/A383G/A553G and A383G/K512E/
A553G), strongly suggesting that Xishuangbanna P. vivax
isolates were highly resistant to sulphadoxine. The high
prevalence of mutant pfdhps alleles is similar to a previous
report in Yunnan province of China (Nu River) [16]. Incontrast, all isolates from Bozhou carried the WT allele,
which is similar to reports from Wuhe county in Anhui
province [31,41] and Luodian county in Guizhou province
[41] of China, Mauritania [33], Iran [38], and Afghanistan
[44]. The absence of mutations in pvdhps in this study in-
dicated that P. vivax populations in Bozhou may still be
effectively susceptible to sulphadoxine.
Molecular epidemiologic studies in different areas have
shown dramatically different mutation rates in pvdhfr and
pvdhps, which may be attributed to different drug-selection
pressures or the intrinsic differences among endemic
strains of P. vivax. It is important to take into account the
presence of A383G mutation of pvdhps along with double
pvdhfr mutations, as SP drug-treatment failure was more
frequently associated with multiple mutations in pvdhfr
and pvdhps [50]; when the P. falciparum parasite carries
mutant alleles of dhfr and dhps, clinical effectiveness of SP
is compromised [51]. In the current study, disregarding
the mutations at codon 99 of pvdhfr, which is not consid-
ered to be related to the anti-malarial drugs, 31.6% of 114
isolates (including Types 8, 14 to 19, and 21 to 28) con-
tained the mutations in pvdhfr and pvdhps and 4.4% of
114 isolates (including Types 16, 19, and 26) mutated sim-
ultaneously in the three drug-resistant genes pvdhfr,
pvdhps, and pvmdr-1 were found in the Xishuangbanna
isolates but not in Bozhou isolates. Although SP was not
recommended to treat P. vivax malaria in China due to
the intensive use of antifolate drugs for treating P. falciparum
infections, P. vivax has been under SP drugs pressure
through mixed infections and/or incorrect diagnosis in
Yunnan. In contrast, without the introduction of sul-
phadoxine in Anhui—where P. vivax is the only or most
predominant malaria parasite, P. vivax is not under sul-
phadoxine but rather pyrimethamine drug pressure.
Therefore, the different usage of antifolate drug in Yunnan
and Anhui may lead to the high prevalence of pvdhfr and
pvdhps mutated alleles in Xishuangbanna isolates and
relatively low prevalence of these mutations in Bozhou
isolates. In tropical area, in addition to longer transmission
period, short-term relapses are more common (1–2
months), leading to increased expose of P. vivax parasites
to sub-therapeutic concentrations of SP and CQ. Regard-
less, the results from this study indicates that the high
prevalence of multiple mutations of pvdhfr, pvdhps, and
pvmdr-1 genes may further reduce the sensitivity to SP
and CQ in P. vivax populations in Xishuangbanna of
Yunnan, while the P. vivax population may still be sus-
ceptible to SP and CQ in Bozhou of central China due
to the absence of multiple mutations in pvdhfr, pvdhps,
and pvmdr-1.
Conclusions
Results from the current study indicate that the prevalence
and patterns of mutant pvdhfr, pvdhps, and pvmdr-1
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(Xishuangbanna, Yunnan) and temperate (Bozhou, Anhui)
zones of China. P. vivax populations in subtropical zone
of China are likely resistant to SP and CQ, whereas in
temperate zone of China they are still relatively susceptible
to SP and CQ, which provides valuable information for
monitoring drug resistance in different malaria-endemic
areas of China and for assessing the appropriateness of the
current national anti-malarial drug policy. The increased
resolution afforded by combination of molecular genetics
and geographic information systems (GIS) tools has the
potential to provide insights into the epidemiology, evolu-
tion, and ecology of these parasites in the future.
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